Reportable Segment — Net Income
Business Segments · Net IncomeEli Lilly Reportable Segment — Net Income increased by 18.9% to $6.64B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 50.5%, from $4.41B to $6.64B. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Net Income shows an upward trend with a 49.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toNet Income
How to read this metric
Consistent growth in net income signals a healthy, scalable business model with effective cost management.
Detailed definition
Represents the final profitability of the segment after accounting for all revenues, operating expenses, and other segme...
Peer comparison
Comparable to segment operating profit or segment net income in peer financial reporting.
Metric ID:
lly_segment_reportable_segment_net_incomeHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.56B | $1.56B | $1.56B | $1.56B | $1.31B | $1.31B | $1.31B | $1.31B | $2.24B | $2.97B | $970.30M | $4.41B | $2.76B | $5.66B | $5.58B | $6.64B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -16.1% | +0.0% | +0.0% | +0.0% | +71.2% | +32.3% | -67.3% | +354.5% | -37.4% | +105.1% | -1.4% | +18.9% |
| YoY Change | — | — | — | — | -16.1% | -16.1% | -16.1% | -16.1% | +71.2% | +126.5% | -25.9% | +236.6% | +23.0% | +90.8% | +475.3% | +50.5% |
Range$970.30M – $6.64B
CAGR+47.1%
Avg YoY Growth+82.0%
Median YoY Growth+36.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — net income?
- Eli Lilly (LLY) reported reportable segment — net income of $6.64B in Q4 2025.
- How has Eli Lilly's reportable segment — net income changed year-over-year?
- Eli Lilly's reportable segment — net income increased by 50.5% year-over-year, from $4.41B to $6.64B.
- What is the long-term trend for Eli Lilly's reportable segment — net income?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — net income has grown at a 49.0% compound annual growth rate (CAGR), from $6.24B to $20.64B.
- What does reportable segment — net income mean?
- The total profit earned by the segment after all associated costs and expenses.